FDA approves Retatrutide this year?
This event asks whether the US FDA will approve a drug whose active ingredient is Eli Lilly's retatrutide, for any use, by the end of 2026 (Eastern Time). The key point is that only a formal FDA approval counts. Complete response letters, delays, and requests for more data do not.
Right now traders give this a 1% chance.
| Market | Chance of yes | Deadline |
|---|---|---|
| FDA approves Retatrutide this year? | 1.3% | Jan 1, 2027, 4:59 UTC |
Odds read from Polymarket at 22:18 UTC on Nov 21, 2026. $599K traded so far, $29 in the last 24 hours.
How this market resolves
Yes: The FDA grants a full or conditional approval (such as an NDA or BLA approval letter, or an sNDA/sBLA for a new use) for a product containing retatrutide, under any brand name, for any use, between market creation and December 31, 2026, 11:59 PM ET.
No: No qualifying FDA approval of a retatrutide product is issued by that deadline. This includes the case where the FDA issues a complete response letter, extends a review date, asks for more information, or simply has not acted yet.
When it really ends
December 31, 2026, 11:59 PM ET (Eastern Time). That is 2027-01-01 04:59 UTC, since ET is UTC-5 in winter. The data's end date of 2027-01-01T04:59:00Z matches the rules.
What counts
- Standard (traditional) approval of a retatrutide product
- Accelerated approval based on surrogate endpoints
- Approval with a REMS (Risk Evaluation and Mitigation Strategy)
- Approval with restricted distribution or limits on the indication
- Approval for any use, under any brand name or identifier such as LY3437943
What does not count
- Complete Response Letters saying the application cannot be approved as submitted
- Approvable letters that require further action, or requests for more information or studies
- Extensions of PDUFA (user fee) goal dates
- Compassionate use or expanded access approvals only
- Emergency Use Authorization without full approval
- Approval only for export or use outside the US, or tentative approvals pending patent or exclusivity expiry
Fine print people miss
- The rules say the market runs from creation to the deadline, so an approval before creation is not clearly covered; the rules do not address this directly.
- An advisory committee vote against approval does not change a Yes if the FDA approves anyway.
- Later withdrawal of an approval does not undo a Yes.
- Post-marketing requirements or commitments attached to an approval still count.
- The main source is official FDA information, backed by consensus of credible reporting.
- The rules do not say whether Lilly has filed an application or when a decision is due, so the market depends on FDA action actually occurring in time.
What moves the price
- News that Lilly has submitted an application, or that the FDA accepted it or granted priority review, would raise the chance of Yes.
- A announced PDUFA decision date before year-end would raise it; a date in 2027 would lower it.
- Strong late-stage trial results and no safety concerns would support Yes; safety signals or missed endpoints would lower it.
- A PDUFA extension, complete response letter, or request for more data would push toward No.
- Use of a priority review voucher or other faster review pathway would raise the chance of Yes.
Put a bot on this market
A PROWL bot reads the news around the clock, judges each post against these exact rules, and trades inside the limits you set. It starts in paper mode.
Questions people ask
What is retatrutide?
Retatrutide is a triple-agonist hormone/peptide drug developed by Eli Lilly. Per the rules, it is in trials for obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and other uses.
When does the Retatrutide FDA approval market end?
It ends on December 31, 2026 at 11:59 PM Eastern Time, which is 2027-01-01 04:59 UTC. Approvals after that moment do not count.
Does approval for only one use count?
Yes. Approval for any use is enough, including a limited or restricted indication.
Does a conditional or accelerated approval count?
Yes. Accelerated approval, approval with a REMS, and approvals with post-marketing requirements all qualify.
What if the FDA delays its decision or issues a complete response letter?
Then the market does not resolve Yes. Delays, PDUFA extensions, and complete response letters are not approvals, so the market stays No unless a real approval comes by the deadline.
Would an advisory committee vote against approval change the result?
No. The rules say a Yes stands if the FDA approves, whatever an advisory committee votes, and even if approval is later withdrawn.
More Science markets explained
Written from the market's own rules text on Nov 16, 2026. If the rules on Polymarket differ from this page, the rules on Polymarket govern.